We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
- Authors
Duminuco, Andrea; Nardo, Antonella; Palumbo, Giuseppe A.
- Abstract
This article discusses the occurrence of lymphoproliferative disorders (LPD) in patients undergoing treatment with the Janus Kinase inhibitor (JAKi) ruxolitinib (RUX) for myelofibrosis (MF). The inhibition of the JAK-STAT pathway by RUX can lead to immunological dysfunction and an increased risk of infections. The article presents two cases where LPD developed during RUX treatment, and switching to the JAK2 inhibitor fedratinib (FED) resulted in complete remission of the LPD while controlling MF symptoms. The authors suggest that FED may be a suitable alternative for patients with indolent lymphoid clones or LPD development during RUX therapy.
- Subjects
MYELOFIBROSIS; LYMPHOPROLIFERATIVE disorders; RUXOLITINIB; DIFFUSE large B-cell lymphomas; MONONUCLEAR leukocytes
- Publication
Hematological Oncology, 2024, Vol 42, Issue 2, p1
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3259